A phase I study of intravenous fenretinide (4-HPR) for patients with malignant solid tumors
Jacob Thomas, Anthony B. El-Khoueiry, Barry J. Maurer, Susan Groshen, Jacek Pinski, Everardo Cobos, David R. Gandara, Heinz Josef Lenz, Min H. Kang, C. Patrick Reynolds, Edward M. Newman
Topics & Concepts
FenretinideMedicinePharmacokineticsAdverse effectPharmacologyInternal medicineMetaboliteActive metaboliteChemotherapyGastroenterologyRetinoidChemistryRetinoic acidBiochemistryGeneRetinoids in leukemia and cellular processesDrug-Induced Ocular ToxicityCancer, Lipids, and Metabolism